These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 22933199)

  • 1. [Glucocorticoids in rheumatic diseases - what is the optimal dose?].
    Krause D
    Dtsch Med Wochenschr; 2012 Sep; 137(36):1751-4. PubMed ID: 22933199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases.
    Duru N; van der Goes MC; Jacobs JW; Andrews T; Boers M; Buttgereit F; Caeyers N; Cutolo M; Halliday S; Da Silva JA; Kirwan JR; Ray D; Rovensky J; Severijns G; Westhovens R; Bijlsma JW
    Ann Rheum Dis; 2013 Dec; 72(12):1905-13. PubMed ID: 23873876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Current topics over updating guidelines on the management and treatment of glucocorticoid-induced osteoporosis].
    Suzuki Y
    Clin Calcium; 2014 Mar; 24(3):417-24. PubMed ID: 24576939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Benefits and risks of glucocorticoid therapy for the treatment of rheumatoid arthritis and management of glucocorticoid-induced osteoporosis].
    Suzuki Y; Wakabayashi T; Saito E; Yamada C; Suwa A
    Clin Calcium; 2009 Mar; 19(3):404-15. PubMed ID: 19252251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bisphosphonates in patients with glucocorticoids: time for implementation.
    Lems WF
    J Rheumatol; 2009 Aug; 36(8):1570-2. PubMed ID: 19671808
    [No Abstract]   [Full Text] [Related]  

  • 6. The safety of low-dose glucocorticoids in rheumatic diseases: results from observational studies.
    Hwang YG; Saag K
    Neuroimmunomodulation; 2015; 22(1-2):72-82. PubMed ID: 25228230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention and treatment of glucocorticoid-induced osteoporosis in daily dermatologic practice.
    Vermaat H; Kirtschig G
    Int J Dermatol; 2008 Jul; 47(7):737-42. PubMed ID: 18613886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Guidelines for the treatment of glucocorticoid-induced osteoporosis and their future problems].
    Soen S
    Clin Calcium; 2006 Nov; 16(11):1788-96. PubMed ID: 17079844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Prophylaxis of glucocorticoid-induced osteoporosis].
    Tanaka Y
    Clin Calcium; 2006 Nov; 16(11):1858-65. PubMed ID: 17079853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Guidelines on the management and treatment of glucocorticoid-induced osteoporosis (2004) in Japan].
    Takayanagi R
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():50-5. PubMed ID: 18161081
    [No Abstract]   [Full Text] [Related]  

  • 11. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis.
    Arthritis Rheum; 2001 Jul; 44(7):1496-503. PubMed ID: 11465699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Glucocorticoid induced osteoporosis].
    Lange U; Müller-Ladner U
    Orthopade; 2007 Apr; 36(4):381-8; quiz 389-90. PubMed ID: 17665509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient and rheumatologist perspectives on glucocorticoids: an exercise to improve the implementation of the European League Against Rheumatism (EULAR) recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases.
    van der Goes MC; Jacobs JW; Boers M; Andrews T; Blom-Bakkers MA; Buttgereit F; Caeyers N; Choy EH; Cutolo M; Da Silva JA; Guillevin L; Holland M; Kirwan JR; Rovensky J; Saag KG; Severijns G; Webber S; Westhovens R; Bijlsma JW
    Ann Rheum Dis; 2010 Jun; 69(6):1015-21. PubMed ID: 19762359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Glucocorticoid induced osteoporosis in childhood: prophylaxis and treatment].
    Tanaka H
    Clin Calcium; 2009 Apr; 19(4):569-73. PubMed ID: 19329838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Active vitamin D3 therapy for gulucocorticoid-induced osteoporosis].
    Nakayama H
    Clin Calcium; 2006 Jul; 16(7):1201-7. PubMed ID: 16816482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucocorticoid-induced osteoporosis: prevention and treatment.
    Werth VP
    Rev Rhum Engl Ed; 1997 Jun; 64(6 Suppl):84S-88S. PubMed ID: 9273946
    [No Abstract]   [Full Text] [Related]  

  • 17. Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice.
    van der Goes MC; Jacobs JW; Boers M; Andrews T; Blom-Bakkers MA; Buttgereit F; Caeyers N; Cutolo M; Da Silva JA; Guillevin L; Kirwan JR; Rovensky J; Severijns G; Webber S; Westhovens R; Bijlsma JW
    Ann Rheum Dis; 2010 Nov; 69(11):1913-9. PubMed ID: 20693273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Biochemical markers of bone turnover. New aspect. Biochemical bone markers of bone in patients treated with glucocorticoid].
    Yamauchi M
    Clin Calcium; 2009 Aug; 19(8):1092-1100. PubMed ID: 19638692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Corticosteroid-induced osteoporosis in neurology patients.
    Gallagher DA; Sturrock A
    Clin Neurol Neurosurg; 2007 Feb; 109(2):218-9. PubMed ID: 16949735
    [No Abstract]   [Full Text] [Related]  

  • 20. Developments in glucocorticoid therapy.
    Bijlsma JW; Saag KG; Buttgereit F; da Silva JA
    Rheum Dis Clin North Am; 2005 Feb; 31(1):1-17, vii. PubMed ID: 15639052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.